Summary of CT antigen expression in ATLL cells from primary ATLL patients
| . | No. of patients . | NY-ESO-1 . | MAGE . | |
|---|---|---|---|---|
| A3 . | A4 . | |||
| Age (mean, 60.6 y) | ||||
| ≥ 60 y | 29 | 20 | 12 | 20 |
| < 60 y | 28 | 15 | 6 | 15 |
| Sex | ||||
| Male | 30 | 17 | 8 | 17 |
| Female | 27 | 18 | 10 | 18 |
| Disease type | ||||
| Aggressive | 40 | 25 (62.5%) | 14 (35.0%) | 26 (65.0%) |
| Acute | 37 | 22 | 13 | 24 |
| Lymphoma | 3 | 3 | 1 | 2 |
| Indolent | 17 | 9 (52.9%) | 4 (23.5%) | 9 (52.9%) |
| Chronic | 11 | 7 | 2 | 8 |
| Smoldering | 6 | 3 | 2 | 1 |
| . | No. of patients . | NY-ESO-1 . | MAGE . | |
|---|---|---|---|---|
| A3 . | A4 . | |||
| Age (mean, 60.6 y) | ||||
| ≥ 60 y | 29 | 20 | 12 | 20 |
| < 60 y | 28 | 15 | 6 | 15 |
| Sex | ||||
| Male | 30 | 17 | 8 | 17 |
| Female | 27 | 18 | 10 | 18 |
| Disease type | ||||
| Aggressive | 40 | 25 (62.5%) | 14 (35.0%) | 26 (65.0%) |
| Acute | 37 | 22 | 13 | 24 |
| Lymphoma | 3 | 3 | 1 | 2 |
| Indolent | 17 | 9 (52.9%) | 4 (23.5%) | 9 (52.9%) |
| Chronic | 11 | 7 | 2 | 8 |
| Smoldering | 6 | 3 | 2 | 1 |
mRNA expression of NY-ESO-1, MAGE-A3, and MAGE-A4 in ATLL cells from primary ATLL patients was analyzed with RT-PCR. CT antigen expression was summarized based on several clinical parameters.